Bionano Announces Publication Showing That OGM Identifies Variant That Indicates Use Of Proven Therapy In Acute Promyelocytic Leukemia

• A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL)
  
   
• The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about 13% of cases of APL, conventional cytogenetics fails to identify the variant(s) that indicate(s) these treatment
  
   
• Identification of this PML::RARA fusion variant by OGM is consistent with previously reported findings which show that OGM can detect variants found by standard cytogenetics and can also find additional variants that are missed by these techniques
  
   

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a publication from the Johns Hopkins University School of Medicine in Genes showing that optical genome mapping (OGM) identifies a variant in an aggressive form of acute myelogenous leukemia (AML) known as acute promyelocytic leukemia, or APL. This variant is often missed by conventional cytogenetic techniques.